Application

19882830 · A CDK9 INHIBITOR FOR USE IN THE TREATMENT OF CANCER IN A SUBJECT HAVING AN ASXL1 MUTATION

Filed 2026-10-06 · Pending The official file ↗ · Art unit · SELLAS LIFE SCIENCES GROUP, INC. · Leason Ellis LLP (Life Sciences)

Office actions

first was

RCEs

no appeal

To first action

n/a

to disposition n/a

Statutes raised

0 actions read

Unlock the prosecution timelineIncluded in Pro, from $29 a month. Cancel any time.